We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Procaps Group SA is a Luxembourg-based healthcare and pharmaceutical company. The Company develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and hi... Procaps Group SA is a Luxembourg-based healthcare and pharmaceutical company. The Company develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. It operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs. Show more
Ask ADVFN Intelligence (AI)
MIAMI and BARRANQUILLA, Colombia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical...
MIAMI and BARRANQUILLA, Colombia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical...
Ruben Minski decides to step down as Executive Chairman and José Minski is appointed as new Chairman of the Board Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading...
Procaps Group (Nasdaq: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it has received a letter from the Nasdaq...
Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it has determined it is unable to file...
Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it has determined it is unable to file...
Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is conducting a process to explore...
Procaps Group (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued a letter to shareholders from Jose Vieira, CEO of...
Dear Shareholders, We became aware on Saturday, January 13, 2024, that the online voting instructions related to the upcoming General Meeting of Shareholders of the Company scheduled for January...
Net Revenues Increased 5% in 9M23 Year-over-Year on a Constant Currency Basis, Driven by 13% RX Growth Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.3794 | 20.2887700535 | 1.87 | 2.25 | 1.68 | 12428 | 2.08093423 | CS |
| 4 | 0.2094 | 10.2647058824 | 2.04 | 2.25 | 1.68 | 8076 | 1.94241233 | CS |
| 12 | -0.2506 | -10.024 | 2.5 | 2.8113 | 1.68 | 5566 | 2.05261293 | CS |
| 26 | -0.7506 | -25.02 | 3 | 3.38 | 1.68 | 5418 | 2.38159245 | CS |
| 52 | -1.5006 | -40.016 | 3.75 | 4.95 | 1.68 | 18691 | 3.05928877 | CS |
| 156 | -6.1606 | -73.2532699168 | 8.41 | 11.98 | 1.68 | 26903 | 6.7640053 | CS |
| 260 | -6.1606 | -73.2532699168 | 8.41 | 11.98 | 1.68 | 26903 | 6.7640053 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
